Another important factor is the acquisition of many genetic mutations, such as KRAS (85–100% of pancreatic cancer cases) and mutations of suppressor genes such as p16 (CDKN2A), TP53, SMAD, and mutations of damage repair genes like hMLH1 [6]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.